Clinical Trial Update: A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures. [Phase 3]

View source ↗

Summary

Phase 3 study evaluating RWJ-333369 as add-on therapy for partial onset seizures in epilepsy, assessing efficacy and safety. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complex Partial Seizures
• Epilepsy
• Partial-onset Seizures

Drugs mentioned

• RWJ 333369 (RWJ-333369)

Snippet

Sponsor: SK Life Science, Inc. | Conditions: Epilepsy, Epilepsy, Focal | Phase 3 | Status: COMPLETED